Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Translesion DNA Polymerases02:10

Translesion DNA Polymerases

10.1K
Translesion (TLS) polymerases rescue stalled DNA polymerases at sites of damaged bases by replacing the replicative polymerase and installing a nucleotide across the damaged site. Doing so, TLS allows additional time for the cell to repair the damage before resuming regular DNA replication.
TLS polymerases are found in all three domains of life - archaea, bacteria, and eukaryotes. Of the different classes of TLS polymerases, members of the Y family are fitted with specialized structures that...
10.1K
In-vitro Mutagenesis01:16

In-vitro Mutagenesis

14.2K
To learn more about the function of a gene, researchers can observe what happens when the gene is inactivated or “knocked out,” by creating genetically engineered knockout animals. Knockout mice have been particularly useful as models for human diseases such as cancer, Parkinson’s disease, and diabetes.
14.2K
Conservative Site-specific Recombination and Phase Variation02:53

Conservative Site-specific Recombination and Phase Variation

6.1K
Because the DNA segments are cut and reorganized in a direction-specific manner, site-specific recombination has emerged as an efficient genetic engineering technique. Flippase and Cyclization recombinases or Flp and Cre, respectively, are two members of the tyrosine recombinase family derived from bacteriophages, that are used to mediate site-specific DNA insertions, deletions, and targeted expression of proteins in mammalian cell lines.
The recognition sites for Cre recombinase called LoxP...
6.1K
Lethal Alleles02:41

Lethal Alleles

15.7K
Agouti: A Lethal Allele
Lucien Cuénot discovered lethal alleles in 1905 while studying the inheritance of coat color in mice. The agouti gene is responsible for the color of the coat in mice. This gene codes for an agouti-signaling protein, which is responsible for melanin distribution in mammals. The wild-type allele gives rise to gray-brown coat color in mice, while the mutant allele gives rise to yellow coat color. In addition to coat color, the agouti gene is associated with the yellow...
15.7K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Selective sensitivity of Ph-like B-cell acute lymphoblastic leukemia to BRG1 inhibition identifies a therapeutic vulnerability.

Leukemia·2026
Same author

ATF4 coordinates amino acid and nucleotide synthesis with selective protein translation to ensure proper DNA replication timing in leukemia cells.

Nature communications·2026
Same author

Single-Nucleotide Polymorphisms in Genes Associated with Mitochondrial and DNA Damage Response Modulate the Risk of Non-Alcoholic Fatty Liver Disease in Humans.

International journal of molecular sciences·2026
Same author

Polθ activity modulates sensitivity to standard therapies in DNMT3A-deficient leukemia.

Cell reports. Medicine·2026
Same author

Correction: Barszczewska-Pietraszek et al. Polθ Inhibitor (ART558) Demonstrates a Synthetic Lethal Effect with PARP and RAD52 Inhibitors in Glioblastoma Cells. <i>Int. J. Mol. Sci.</i> 2024, <i>25</i>, 9134.

International journal of molecular sciences·2026
Same author

Selective Cytotoxicity of Ochratoxin A: Pro-Apoptotic Effects on Healthy Immune Cells Compared to Leukemia Cells.

Molecules (Basel, Switzerland)·2025

Related Experiment Video

Updated: Sep 6, 2025

A Data Integration Workflow to Identify Drug Combinations Targeting Synthetic Lethal Interactions
07:40

A Data Integration Workflow to Identify Drug Combinations Targeting Synthetic Lethal Interactions

Published on: May 27, 2021

4.3K

Synthetic Lethality Targeting Polθ.

Małgorzata Drzewiecka1, Gabriela Barszczewska-Pietraszek1, Piotr Czarny2

  • 1Laboratory of Medical Genetics, Faculty of Biology and Environmental Protection, University of Lodz, 90-236 Lodz, Poland.

Genes
|June 24, 2022
PubMed
Summary

Synthetic lethality offers a targeted cancer therapy approach. Inhibiting DNA polymerase theta (Polθ) in homologous recombination repair-deficient tumors can induce synthetic lethality, overcoming resistance to other therapies.

Keywords:
DNA damageDNA repairpersonalized medicinepolymerase thetasynthetic lethality

More Related Videos

Author Spotlight: Developing Novel Anticancer Therapeutics Targeting the DNA Damage Response
05:01

Author Spotlight: Developing Novel Anticancer Therapeutics Targeting the DNA Damage Response

Published on: June 14, 2024

1.5K
Genetic Manipulation in &Delta;ku80 Strains for Functional Genomic Analysis of Toxoplasma gondii
09:52

Genetic Manipulation in Δku80 Strains for Functional Genomic Analysis of Toxoplasma gondii

Published on: July 12, 2013

17.2K

Related Experiment Videos

Last Updated: Sep 6, 2025

A Data Integration Workflow to Identify Drug Combinations Targeting Synthetic Lethal Interactions
07:40

A Data Integration Workflow to Identify Drug Combinations Targeting Synthetic Lethal Interactions

Published on: May 27, 2021

4.3K
Author Spotlight: Developing Novel Anticancer Therapeutics Targeting the DNA Damage Response
05:01

Author Spotlight: Developing Novel Anticancer Therapeutics Targeting the DNA Damage Response

Published on: June 14, 2024

1.5K
Genetic Manipulation in &Delta;ku80 Strains for Functional Genomic Analysis of Toxoplasma gondii
09:52

Genetic Manipulation in Δku80 Strains for Functional Genomic Analysis of Toxoplasma gondii

Published on: July 12, 2013

17.2K

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Synthetic lethality (SL) is a promising strategy for cancer chemotherapy, targeting cancer cells while sparing normal cells.
  • DNA repair pathways are key targets for inducing SL, especially in cancer cells with mutations in canonical repair mechanisms.
  • Resistance to current therapies like PARP1 inhibitors (PARPi) necessitates novel therapeutic targets.

Purpose of the Study:

  • To review the potential of DNA polymerase theta (Polθ) as a target for synthetic lethality-based cancer therapies.
  • To explore the role of Polθ in the theta-mediated end joining (TMEJ) DNA repair pathway.
  • To discuss the implications of Polθ inhibition in tumors with homologous recombination repair (HRR) deficiencies.

Main Methods:

  • Literature review of current research on synthetic lethality and DNA repair pathways.
  • Analysis of the role of DNA polymerase theta (Polθ) in double-strand break (DSB) repair.
  • Examination of therapeutic strategies targeting Polθ in cancer treatment.

Main Results:

  • Polθ is crucial for the alternative TMEJ DNA repair pathway.
  • Inhibition of Polθ can induce synthetic lethality in homologous recombination repair (HRR)-deficient cancer cells.
  • Polθ represents a potential therapeutic target to overcome resistance to existing cancer treatments.

Conclusions:

  • DNA polymerase theta (Polθ) is a viable target for developing novel synthetic lethality-based anticancer therapies.
  • Targeting Polθ offers a strategy to treat tumors resistant to current therapies, particularly those with HRR deficiencies.
  • Further research into Polθ inhibitors is warranted for effective cancer treatment protocols.